FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Haynes Boone Represents ProPath in Sale to Sonic Healthcare

December 27, 2021, 08:00 AM
Filed Under: Industry News

A Haynes and Boone deal team represented ProPath in connection with its recent sale to Sonic Healthcare (Sonic). The transaction closed Dec. 17, 2021.

ProPath is a physician led anatomical and clinical pathology (AP) practice, routinely diagnosing cases from 45 states and several foreign countries. ProPath is highly regarded as a pre-eminent AP practice, with an exceptionally strong brand, reputation and leadership team that has been based in Dallas, Texas since 1966. In early 2020, ProPath acquired New England Tissue, an AP company located in Massachusetts.

Headquartered in Sydney, Australia, Sonic has grown to become one of the world’s leading healthcare providers, with specialist operations in Australasia, Europe and North America, providing laboratory medicine / pathology, radiology, general practice medicine and corporate medical services.

In a press statement, Sonic said the acquisition of ProPath is a significant additional step in the ongoing development of Sonic’s AP and clinical laboratory operations in the U.S. and is part of Sonic’s long-term strategy of integrating the disciplines of anatomical pathology and clinical laboratory testing together as a seamless service in the U.S.

“The Haynes and Boone team was the perfect choice for us. They combined keen intellect, savvy business skills, extensive deal experience and common-sense logic that led to a great outcome for the ProPath members,” said ProPath CEO Cory A. Roberts, MD, MBA.

ProPath was represented by a Haynes Boone deal team led by Corporate Partner John McGowan, who has significant experience handling acquisitions, divestitures, securities transactions, and other complex corporate matters across multiple sectors including healthcare and life sciences.


Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.